Q-omics provides the consensus-scored NUS1P2 profile across patient tissues and cancer cell-line models. NUS1P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NUS1P2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, NUS1P2 RNA expression shows 15,175 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KICH, and THYM as cancer lineages where NUS1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUS1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUS1P2 survival associations across molecular data types. NUS1P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUS1P2 RNA expression–survival associations across cancer types. High NUS1P2 expression shows unfavorable associations in KICH, LUAD and ACC, but favorable associations in BRCA, KIRC and ESCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for NUS1P2 RNA expression.
This table summarizes NUS1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NUS1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUS1P2 shows lower tumor expression in KICH and COAD and higher tumor expression in LUAD, KIRP, UCEC and KIRC. The KICH box plot shows higher NUS1P2 RNA expression in normal versus tumor tissue (log2 FC = −3.001, t-test p < 0.001).
This table shows molecular features associated with NUS1P2 in patient tissues and cancer cell lines. In patient samples, NUS1P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
